Literature DB >> 34431024

In reply to: Christ J, Herndon CN, Yu B. Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients. J Assist Reprod Genet. 2021;38:751-6. doi:10.1007/s10815-020-02051.

Avi Tsafrir1, Ariel Weissman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34431024      PMCID： PMC8581150          DOI： 10.1007/s10815-021-02305-y

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN： 1058-0468            Impact factor:   3.357


× No keyword cloud information.
  8 in total

Review 1.  GnRH agonist for triggering of final oocyte maturation: time for a change of practice?

Authors:  P Humaidan; S Kol; E G Papanikolaou
Journal:  Hum Reprod Update       Date:  2011-03-30       Impact factor: 15.610

2.  GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.

Authors:  G Griesinger; K Diedrich; P Devroey; E M Kolibianakis
Journal:  Hum Reprod Update       Date:  2005-10-27       Impact factor: 15.610

3.  Luteal phase support with GnRH agonist does not eliminate the risk for ovarian hyperstimulation syndrome.

Authors:  Shevach Friedler; Leonti Grin
Journal:  Gynecol Endocrinol       Date:  2019-01-07       Impact factor: 2.260

4.  Gonadotropin-releasing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles.

Authors:  Itai Bar Hava; Moran Blueshtein; Hadas Ganer Herman; Yeela Omer; Gila Ben David
Journal:  Fertil Steril       Date:  2016-10-27       Impact factor: 7.329

5.  Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.

Authors:  Itai Bar-Hava; Yossi Mizrachi; Daphne Karfunkel-Doron; Yeela Omer; Liron Sheena; Nurit Carmon; Gila Ben-David
Journal:  Fertil Steril       Date:  2016-04-22       Impact factor: 7.329

6.  Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.

Authors:  Ayse Seyhan; Baris Ata; Mehtap Polat; Weon-Young Son; Hakan Yarali; Michael H Dahan
Journal:  Hum Reprod       Date:  2013-04-30       Impact factor: 6.918

7.  Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support-Results of a Prospective, Randomized, Comparative Study.

Authors:  Céline Pirard; Ernest Loumaye; Pascale Laurent; Christine Wyns
Journal:  Int J Endocrinol       Date:  2015-04-05       Impact factor: 3.257

8.  Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients.

Authors:  Jacob Christ; Christopher N Herndon; Bo Yu
Journal:  J Assist Reprod Genet       Date:  2021-01-20       Impact factor: 3.412
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.